Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...
“We estimate that around 18,000 New Zealanders with chronic heart failure will benefit in the first year of funding empagliflozin, rising to over 37,000 people per year after five years of funding.
Drawing inferences from observational data with possible confounding Heart failure is increasing in prevalence and is a major cause of morbidity and mortality worldwide,1 with prevalence ranging from ...
The combination of heart failure and anemia can lead to decreased exercise tolerance, increased fatigue, and impaired quality of life. Anemia in heart failure patients may be caused by various factors ...
Notable LLMs include GPT-4o by Open AI, Claude 3.5 Sonnet by Anthropic, and Gemini by Google. This scoping review aims to synthesize the current applications and potential uses of LLMs in patient ...
If you are living with heart failure that is no longer responding to conventional heart therapies and your symptoms are getting worse, you may have advanced heart disease. About 6.2 million people are ...
While the standard treatment, temporary ventricular assist devices (VADs), work for many patients, they may not be suitable in cases of severe biventricular heart failure or univentricular heart ...